In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs
of distant metastases will be treated with short-term immunotherapy + COX2-inhibitors. This
treatment will be given during the window period until surgical resection of the tumor. The
duration of treatment will be approximately 6 weeks.